Mometasone/formoterol - Merck & Co / Novartis

Drug Profile

Mometasone/formoterol - Merck & Co / Novartis

Alternative Names: Dulera; Formoterol/mometasone; MF/F; MFF 258; MK-0887A; MK-08887A; MK-887A; Mometasone furoate/formoterol fumarate; SCH 418131; Zenhale

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Merck & Co; Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • No development reported Allergic asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Dec 2017 Merck Sharp & Dohme completes a phase III trial in Asthma (In children) in Latvia, Hungary, Denmark, Guatemala, Mexico, Romania, South Africa and USA (Inhalation) (NCT02741271) (EudraCT 2009-010110-30)
  • 15 Mar 2016 Phase-III clinical trials in Asthma (In children) in Latvia and Hungary (Inhalation) (EudraCT2009-010110-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top